Modalis Therapeutics

Modalis Therapeutics Equity

The The Equity of Modalis Therapeutics (4883.T) as of Nov 19, 2026 is 2.79 B JPY. In the previous year, The Equity was 3.55 B JPY — a change of -21.27% (lower).

Equity

2.79 BJPY

YoY

-21.27%

Last updated:

In 2025, Modalis Therapeutics's equity was 2.79 B JPY, a -21.27% increase from the 3.55 B JPY equity in the previous year.

The Modalis Therapeutics Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
1.20 B JPY
Jan 1, 2019
3.84 B JPY
Jan 1, 2020
6.21 B JPY
Jan 1, 2021
5.55 B JPY
Jan 1, 2022
2.94 B JPY
Jan 1, 2023
1.38 B JPY
Jan 1, 2024
3.55 B JPY
Jan 1, 2025
2.79 B JPY
The Modalis Therapeutics Equity history
YEAREquityYoY
2.79 BJPY-21.27%
3.55 BJPY+157.03%
1.38 BJPY-53.07%
2.94 BJPY-47.00%
5.55 BJPY-10.60%
6.21 BJPY+61.55%
3.84 BJPY+219.69%
1.20 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Modalis Therapeutics Stock analysis

What does Modalis Therapeutics do? Modalis Therapeutics is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Modalis Therapeutics's Equity

Modalis Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Modalis Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Modalis Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Modalis Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Modalis Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Modalis Therapeutics stock

The Equity of Modalis Therapeutics is 2.79 B JPY in 2025.

The Equity of Modalis Therapeutics changed from 3.55 B JPY to 2.79 B JPY, representing a -21.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Modalis Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The Equity's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Modalis Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Modalis Therapeutics

All Key Metrics — Modalis Therapeutics